Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Head & Neck 3Gynecologic 3Plasma cell 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Vomiting 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Gynecologic Cancer 1

Interventions

Paclitaxel 581Carboplatin 527Cisplatin 355Bevacizumab 256pembrolizumab 226Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 126Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 90niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 73Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 56Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
fosaprepitant × Gynecologic × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

NCT05564286 2024-02-06

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Shantou University Medical College

Phase 3 Completed
116 enrolled
GynecologicHead & Neck

Uterine Cervical Neoplasms, Nasopharyngeal Neoplasms, Vomiting

NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Gynecologic Oncology Associates

Phase 4 Completed
20 enrolled 5 charts
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡